West LA Times

GT Biopharma, Inc. issued the following announcement on Feb. 24.

GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, announced today that GT Biopharma will be participating in the following upcoming medical conferences:

Abstract and poster presentation details are as follows:

ESMO Targeted Anticancer Therapies Congress (TAT) (March 7-8, 2022)
Title:	Driving NK cell immunotherapy against NSCLC, in the context of hypoxia, using Tri-specific Killer Engager (TriKE)
Abstract Number:	250
Session:	Immunotherapy
Presentation Type:	Poster
Session Date and Time:	March 7, 9:20AM (CET) (On-demand e-poster display)
Location:	Virtual
Poster Board Number:	17P

48th Annual European Society for Blood and Marrow Transplantation (EBMT) (March 19-23, 2022)
Title:	A Tri-specific Killer Engager (TriKE) against B7-H3 enhances NK cell mediated killing of multiple myeloma
Abstract Number:	AS-EBMT-2022-00508
Session:	New Drugs- and Cell-Based Immune Therapies
Presentation Type:	Poster
Session Date and Time:	March 19, 2022, 9:50 AM (CET)
Location:	Prague Congress Center, Czech Republic
Poster Board Number:	P153

American Association for Cancer Research (AACR) Annual Meeting (April 8-13, 2022)
Title:	GTB-5550 (cam16-IL15-camB7H3) Tri-specific Killer Engager (TriKE®) drives natural killer cell activation and antibody dependent cellular cytotoxicity against head and neck squamous cell carcinomas
Abstract Number:	Abstract control number 3334, permanent abstract number 3435
Session:	Clinical Research Excluding Trials, Combination Immunotherapies / Therapeutic Antibodies
Presentation Type:	Poster
Session Date and Time:	April 12, 2022 1:30 PM – 5:00 PM
Location:	Ernest N. Memorial Convention Center, Exhibit Halls D-H, Poster Section 32, New Orleans
Poster Board Number:	16

Original source can be found here.

Source: GT Biopharma, Inc.